{"id":"mcc-crm","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains meningococcal C polysaccharide conjugated to a carrier protein (likely CRM197, a non-toxic diphtheria toxin variant), which enhances immunogenicity by promoting T-cell dependent B-cell responses. This conjugation approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by serogroup C strains.","oneSentence":"MCC-CRM is a meningococcal C conjugate vaccine that stimulates immune responses against Neisseria meningitidis serogroup C through conjugation of the polysaccharide capsule to a carrier protein.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:24.148Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C"}]},"trialDetails":[{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MENJUGATE®"],"phase":"phase_3","status":"active","brandName":"MCC-CRM","genericName":"MCC-CRM","companyName":"MCM Vaccines B.V.","companyId":"mcm-vaccines-b-v","modality":"Biologic","firstApprovalDate":"","aiSummary":"MCC-CRM is a meningococcal C conjugate vaccine that stimulates immune responses against Neisseria meningitidis serogroup C through conjugation of the polysaccharide capsule to a carrier protein. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}